MBX Biosciences MBX 深 滬
已收盤 08-07 16:00:00 美东时间
67.82
+0.710
+1.06%
華盛通- 最 高70.00
- 今 開69.69
- 成交量 54.55万股
- 最 低 65.255
- 昨 收 67.11
- 總市值 32.28亿
- 52周最高 72.64
- 市盈率 靜 --
- 換手率 1.15%
- 52周最低 9.63
- 委 比 -4.76%
- 總股本 4759.75万
- 歷史最高 72.64
- 量 比 1.02
- 振 幅 7.07%
- 歷史最低 4.8069
- 每 手 1
- 風險率 13.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多MBX Biosciences GAAP EPS of -$0.78
MBX Biosciences press release (MBX): Q2 GAAP EPS of -$0.78. Cash and Cash Equivalents and Marketable Securities: As of June 30, 2026, MBX had cash, cash equivalents and marketable securities of $418.6...
08-06 20:19
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights
MBX Biosciences reported Q2 2026 financial results with $418.6 million in cash and investments, supporting operations into 2029. Key highlights include: Phase 2 and one-year OLE data for weekly canvuparatide showing sustained benefit for chronic hypoparathyroidism, with Phase 3 trial recruitment ongoing. Initial Phase 1 data for monthly dosing MBX 4291 in obesity showed 7% weight loss. MBX 6180, a triple GLP-1/GIP/GCG agonist, was nominated as a ...
08-06 12:00
美股大行评级 | 最高1400美元！花旗、大小摩8家大行上调希捷科技目标价；大行集中调整目标价：康宁、科斯塔、思佳讯遭下调，PayPal、Visa、可口可乐、赛莱默获上调
今日重点评级关注：古根海姆：维持ProMIS Neurosciences"买入"评级，目标价从35美元升至69美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从38美元升至39美元
07-30 11:45
Mizuho Maintains Outperform on MBX Biosciences, Raises Price Target to $91
Mizuho analyst Uy Ear maintains MBX Biosciences (NASDAQ:MBX) with a Outperform and raises the price target from $57 to $91.
07-29 23:50
MBX Biosciences Appoints Steve Hoerter As Chairman And CEO, Succeeding Kent Hawryluk, With John Smither Named Interim CFO, Effective Immediately
MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that its Board of Directors has appointed Steve Hoer...
07-14 04:19
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth
MBX Biosciences announces leadership changes: Steve Hoerter appointed as CEO, replacing Kent Hawryluk, and John Smither as CFO. Hoerter, a biotech veteran, succeeds Hawryluk, who co-founded the company and led its growth. The company remains focused on advancing precision peptide therapies for endocrine and metabolic disorders, with key milestones expected in 2026.
07-13 20:15
MBX Biosciences Announces Full Results From 12-Week Avail Phase 2 Trial And New 1-Yr Data From Ongoing OLE Study Of Once-Weekly Canvuparatide In Adult Patients With Chronic Hypoparathyroidism
Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial Results consistent with restoration of systemic PTH activity through serum calcium normalization, reduction of urine calcium excretion, restoration of bone metabolism and increase of...
06-12 19:02
Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
